Understanding Hematopoiesis and working with PXP System
Hematopoiesis is the process that creates blood cells. The monophyletic theory in Hematopoiesis, which is widely accepted, suggests that all hematopoietic cells are generated based on pluripotent stem cells, making them unipotential and differentiated into precursor cells before continuing to form mature blood cells.
Hematopoiesis during the early stages of embryogenesis occurs in the egg yolk sac and later in the liver. During the 3rd to 7th month of gestation, it occurs mainly in the spleen, and moments before birth, it changes to the marrow cavity, and from birth onwards, it occurs primarily in the medulla. Pluripotent stem cells continually produce more of themselves. Hematopoietic cells are continuously created from pluripotent stem cells, where a portion of these pluripotent cells become unit potential stem cells. Subsequently, some of the cells of this unit likely population distinguish into precursor cells which, once determined, are in the compromised part developing from the mature types of blood cells, which are erythrocytes, monocytes, lymphocytes, platelets, and granulocytes.
Hematopoietic cells that are immature precursor cells develop from cells that make a lot of protein to cells that make less protein, and structural changes occur with this evolution. These cells have clumped or condensed chromatin since it is not actively being transcribed. In addition to this, these cells have fewer nucleoli, smaller Golgi apparatus, and fewer ribosomes. Thus, they exhibit the less basophilic staining of hematoxylin.
Working with the PXP System
PXP Systems is a functionally closed semi-automatic system that collects the correct amount of cell concentrate from a fixed aspirated bone marrow sample. PXP has consistently high recovery rates for mononuclear cells (MNC) and CD34 + progenitor cells, reduces contaminated red blood cells by 98% or more, granulocytes (GRN) by 80%, and bone marrow concentration by less. 20 minutes. It can be generated. PXP, together with Cesca’s CAR-TXpress and related X-series systems, constitutes a portfolio of clinically highly differentiated cell therapy solutions.
Haihong Zhu, President of ThermoGenesis, said this is new for clinicians who need automated cell treatment products that can streamline their manufacturing processes, especially for the emerging CAR-T immunotherapy market high-cost drugs and low doses represent significant barriers to application. Improve your ability to provide innovative solutions. ThermoGenesis Corp, a privately held company, owned by Cesca Therapeutics (Nasdaq: KOOL) and a market leader in automated cell therapy and autologous cell therapy in regenerative medicine, received the PXP point of approval from the Canadian Department of Health. -Care system for the collection of mononuclear cells and purified platelets from blood or bone marrow
The PXP system addresses many of the shortcomings of currently available methods, such as red blood cell contamination in the resulting cell concentrate, which is believed to reduce the effectiveness of cell-based therapies. Physicians can achieve very high results quickly. High recovery of stem and progenitor cells with minimal RBC and GRN contamination. ”
To Sum Up
The PXP system will be efficient, quick and straightforward to use, precise, and of persistent quality control. The PXP systems will comprise PXP Disposable Cartridge, PXP Control Module, PXP Docking station, PXP DataTrak Software.
